A real-world retrospective cohort study: the clinical outcomes and characteristics of platinum-resistant recurrent ovarian cancer.

Transl Cancer Res · 2025 · PMC12170032 · PMID 40530141

Europe PMC DOI

hedged sentence

0.3200

closest p · 6.4× alpha

0.3200

boldest claim

The sentences

showed a trendP=0.32not close (p > 0.1)

Compared with patients undergoing single-agent chemotherapy alone, those who received additional Bev showed a trend towards prolonged OS (13.2 vs. 12.8 months, HR: 1.141, 95% CI: 0.876–1.486, P=0.32) and median PFS (4.1 vs. 3.6 months, HR: 1.265, 95% CI: 0.966–1.657, P=0.06) ( Figure 3C,3D ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.